Anti-lymphocyte monoclonal antibodies (Formulary)

RITUXIMAB

Important: Therapy notes


Risk minimisation materials

Important: Formulation and dosage details

Formulation:

Solution for subcutaneous injection 120mg/mL (specialist use only)

Dosage:

See SMC advice 33/03, 135/04, 330/06, 591/09, 675/11, 975/14 and NICE guidance TA137, TA065. Also for selected patients with CD 20+ B-cell lymphomas/lymphoproliferative and haematological autoimmune disorders off-label.

Editorial Information

Document Id: F289